Key Takeaways
- Full-year 2026 revenue reached $55.2M versus $50.4M in 2024, while gross margin held steady at 51.2%
- First quarter 2026 brought in $14.9M in revenue compared to $13.1M year-over-year, with margin expansion to 52.7%
- The company secured 238 design wins during 2025, a significant increase from 178 in 2024, with anticipated production ramp in 2026–2027
- A $40M military and aerospace MRAM agreement aligns with U.S. domestic manufacturing priorities
- Shares hover around $27 while Wall Street’s limited analyst coverage suggests price targets between $14–$18.50, with ratings divided between Buy and Sell
Everspin Technologies stands out in the semiconductor landscape as a focused MRAM provider experiencing genuine expansion. However, with shares trading around $27 against substantially lower analyst projections, the central debate shifts from operational execution to valuation justification.
Everspin Technologies, Inc., MRAM
ESMT currently commands a market capitalization approaching $624.5 million. Considering annual revenue remains below $60 million, this multiple appears elevated by conventional metrics.
Financial performance shows consistent expansion
The company recorded $55.2 million in revenue for full-year 2025, representing growth from the prior year’s $50.4 million. MRAM product sales formed the core of this advancement, climbing to $48.3 million from $42.2 million. Profitability metrics remained stable with gross margin at 51.2%.
The first quarter of 2026 continued this upward trajectory. Revenue totaled $14.9 million, exceeding the $13.1 million generated in the comparable 2025 period. MRAM product sales specifically grew to $14.1 million, while gross margin strengthened to 52.7%.
Company leadership highlighted growing demand spanning industrial automation, transportation infrastructure, and data center deployments. This diversification across multiple sectors suggests resilience, as performance becomes less dependent on any single customer relationship or market vertical.
One area requiring attention: licensing and royalty income decreased in both full-year 2025 and Q1 2026, contrasting with the product sales trajectory. This divergence highlights complexity in the revenue composition that warrants monitoring.
Pipeline strength and government contracts bolster growth narrative
The design win pipeline expanded to 238 throughout 2025, marking substantial progress from the 178 recorded in 2024. Company executives anticipate these engagements will transition into volume production across 2026 and 2027. In semiconductor markets, current design activity typically translates into future revenue streams—assuming customers proceed to full deployment.
Late April brought announcement of a $40 million agreement focused on military and aerospace MRAM applications, connected to U.S. domestic Toggle MRAM manufacturing and federal procurement priorities. For an organization of Everspin’s scale, this contract represents material business impact.
The defense sector component introduces additional stability. Military and aerospace programs typically feature extended lifecycles and face reduced exposure to cyclical consumer or enterprise demand fluctuations.
Valuation presents the primary challenge
Wall Street coverage remains extremely limited with only two analysts tracking ESMT. Their recommendations split evenly: one maintains a Buy rating while the other assigns a Sell. This division reflects fundamental disagreement about fair value.
Consensus price targets range from $14.00 to $18.50 across available research. Current trading levels near $27 create a substantial premium above these projections. This disparity demands serious consideration.
Current pricing implies expectations of flawless execution going forward. Should design wins convert smoothly into production revenue and the defense contract deliver according to plan, the premium valuation might prove justified.
Most recent operational data includes Q1 2026 revenue of $14.9 million alongside the $40 million military-aerospace contract announcement from late April.
